According to a report by journalnow on January 22, the US Food and Drug Administration (FDA) has rejected Bidi Vapor LLC's market application for the Bidi Stick Classic e-cigarette.
After the FDA issued a marketing denial order, Bidi vapour company has been prohibited from selling or distributing its product in the US market, otherwise it will face enforcement actions from the FDA. However, Bidi vapour company has the right to submit a new marketing application to the FDA.
According to the FDA's requirements, e-cigarette manufacturers must prove that their products not only serve as a reduced-risk alternative for adult smokers but also ensure that the transition to their products does not result in the illegal use of these products by individuals under the age of 21. However, the FDA believes that Bidi Vapor Company has failed to meet these evidentiary requirements.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
